

## Supplementary materials

Sungyang Jo, MD<sup>1,†</sup>; Woorim Kang, BS<sup>2,3,†</sup>; Yun Su Hwang, MD<sup>1</sup>; Seung Hyun Lee, MD<sup>1</sup>; Kye Won Park, MD<sup>4</sup>; Ja Yeon Do, BS<sup>1</sup>; Mi Sun Kim, RN, PhD<sup>1</sup>; Hyunna Lee, PhD<sup>5</sup>; Hyung Jeong Yoon, BS<sup>6</sup>; Yoo Kyung Park, PhD<sup>6</sup>; Mauricio Chalita, PhD<sup>3</sup>; Je Hee Lee, PhD<sup>3</sup>; Hojun Sung, BS<sup>2</sup>; Jae-Yun Lee, BS<sup>2</sup>; Jin-Woo Bae, PhD<sup>2</sup>; Sun Ju Chung MD, PhD<sup>1</sup>

**†These authors equally contributed to the manuscript**

**Supplementary Figure 1.** Study flowchart

**Supplementary Figure 2.** Comparison of alpha diversity indices between patients with Parkinson's disease (PD) and healthy controls (a) in the stool and (b) in oral samples using 16S rRNA sequencing

**Supplementary Figure 3.** Gut and oral microbiota associated with disease severity in Parkinson's disease (PD) using 16s rRNA sequencing.

**Supplementary Figure 4.** Correlation between clinical symptoms and gut microbial abundance

**Supplementary Figure 5.** Glutamate and arginine synthesis-associated pathway maps


**Supplementary Figure 6.** Variable importance of features in random forest classification models

**Supplementary Table 1.** Baseline clinical characteristics of patients with Parkinson's disease (PD) and healthy controls with complete stool sequencing data.


**Supplementary Table 2.** Baseline clinical characteristics of patients with Parkinson's disease (PD) and healthy controls with complete oral sequencing data.

**Supplementary Table 3.** Functional biomarkers of the oral microbiome using PICRUSt


**Supplementary Table 4.** Correlation between clinical symptoms and gut microbial abundance




**Supplementary Figure 1.** Study flowchart.



**Supplementary Figure 2.** Comparison of alpha diversity indices between patients with Parkinson's disease (PD) and healthy controls (a) in the stool and (b) in oral samples using 16S rRNA sequencing. Boxplot centerline represents the median (50th percentile). The top and bottom hinges represent 75th and 25th percentiles, respectively. The upper and lower whiskers correspond to the highest and lowest data points. n.s : not significant,  $*P < 0.05$ ,  $**P < 0.01$




**Supplementary Figure 3.** Gut and oral microbiota associated with disease severity in Parkinson's disease (PD) using 16s rRNA sequencing. (a) Comparison of beta-diversity between mild PD, severe PD, and healthy controls for gut microbiome (b) Comparison of gut microbiome between mild PD and severe PD using LefSe analysis (c) Comparison of beta-diversity between mild PD, severe PD, and healthy controls for oral microbiome (d) Comparison of oral microbiome between mild PD and severe PD using LefSe analysis




**Supplementary Figure 4.** Correlation between clinical symptoms and gut microbial abundance. (a) Canonical correlation analysis between Parkinson's disease-related clinical features and gut microbial abundance. (b-c) linear regression analysis between UPDRS and (b) stool *Bifidobacterium*, and (c) stool *Lactobacillus* (d) linear regression analysis between stool firmness and stool *Prevotella*.


**a** Glutamate and GABA biosynthesis (from ko00250, k00910)




**b** Glutamate biosynthesis from carbohydrates (from ko00500, ko00010, ko00020, ko00020, 00250, ko00910)




**c** Glutamate biosynthesis during purine metabolism (from ko00250)



**d** Arginine biosynthesis (from ko00220, ko00910)



**Supplementary Figure 5.** Glutamate and arginine synthesis-associated pathway maps. Bar plots indicate mean abundance of genes and error bars represent standard deviation, \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .



Supplementary Figure 6. Variable importance of features in random forest classification models.



**Supplementary Table 1.** Baseline clinical characteristics of patients with Parkinson’s disease (PD) and healthy controls with complete stool sequencing data.

	<b>PD (n=88)</b>	<b>Controls (n=84)</b>	<b><i>p</i> value</b>
Age, years	65.1 ± 7.8	64.7 ± 8.1	0.734
Male, n (%)	47 (53.4%)	39 (46.4%)	0.446
BMI, kg/m <sup>2</sup>	24.3 (22.2–26.2)	23.9 (21.5–25.4)	0.106
Education, years	12.0 (12.0–16.0)	12.0 (12.0–16.0)	0.980
<b>Clinical symptoms</b>			
IBS, n (%)	3 (3.4%)	3 (3.6%)	1.000
Constipation, n (%)	41 (46.6%)	10 (11.9%)	<0.001
Bristol	4.0 (2.0– 4.0)	4.0 (4.0– 4.0)	<0.001
Swallowing test	0.0 (0.0– 3.0)	0.0 (0.0– 0.0)	0.003
Smell test	9.0 (6.0–10.0)	10.0 (10.0–10.0)	<0.001
Disease duration	2.5 (0.0– 6.5)	-	
<b>UPDRS</b>			
UPDRS part 1	5.0 (3.0– 7.0)	-	
UPDRS part 2	7.0 (4.0–11.0)		
UPDRS part 3	32.0 (25.0–40.0)		
UPDRS part 4	0.0 (0.0– 2.0)		
UPDRS total score	45.0 (34.5–60.5)		
Hoehn and Yahr stage	2.0 (2.0– 3.0)		
<b>Medication for PD</b>			
Levodopa use, n (%)	73 (83.0%)	-	

Dopamine agonist, n (%)	34 (38.6%)	-	
COMT inhibitor, n (%)	7 (8.0%)	-	
MAO-B inhibitor, n (%)	25 (28.4%)	-	
Amantadine, n (%)	19 (21.6%)	-	
Levodopa equivalent daily dose (mg)	455.0 (300.0–822.2)	-	
Daily dietary intake	(n=80)	(n=77)	
Total energy (kCal)	2183.0 ± 503.8	2154.8 ± 568.2	0.743
Carbohydrate (g)	297.7 ± 68.8	287.9 ± 80.0	0.415
Protein (g)	88.9 ± 26.0	88.8 ± 25.3	0.975
- animal source	47.9 ± 15.3	47.1 ± 16.6	0.758
- plant source	41.0 ± 16.7	41.7 ± 16.4	0.806
Fat intake (g)	69.5 ± 26.3	67.7 ± 24.3	0.665
- animal source	41.0 ± 19.8	38.8 ± 18.5	0.482
- plant source	28.5 ± 13.1	28.9 ± 12.9	0.847
Fiber (g)	39.0 ± 17.0	38.0 ± 17.7	0.727
- Soluble fiber	5.1 ± 2.5	5.1 ± 2.4	0.959
- Insoluble fiber	19.1 ± 8.1	19.2 ± 8.6	0.944

**Supplementary Table 2.** Baseline clinical characteristics of patients with Parkinson’s disease (PD) and healthy controls with complete oral sequencing data.

	<b>PD (n=74)</b>	<b>Controls (n=69)</b>	<b><i>p</i> value</b>
Age, years	65.0 ± 7.6	64.9 ± 7.5	0.911
Male, n (%)	42 (56.8%)	33 (47.8%)	0.368
BMI, kg/m <sup>2</sup>	24.3 (22.3–26.3)	24.1 (22.0–25.7)	0.492
Education, years	12.0 (12.0–16.0)	12.0 (10.5–16.0)	0.915
Clinical symptoms			
IBS, n (%)	2 (2.7%)	2 (2.9%)	1.000
Constipation, n (%)	34 (45.9%)	8 (11.6%)	<0.001
Bristol	4.0 (2.0– 4.0)	4.0 (4.0– 4.0)	<0.001
Swallowing test	0.0 (0.0– 3.0)	0.0 (0.0– 0.0)	0.008
Smell test	9.5 (6.0–10.0)	10.0 (10.0–10.0)	<0.001
Disease duration	2.0 (0.0– 6.0)	-	
UPDRS			
UPDRS part 1	5.0 (3.0– 8.0)	-	
UPDRS part 2	7.0 (3.0–11.0)		
UPDRS part 3	32.0 (23.0–41.0)		
UPDRS part 4	0.0 (0.0– 0.0)		
UPDRS total score	43.0 (34.0–61.0)		
Hoehn and Yahr stage	2.0 (2.0– 3.0)		
Medication for PD			
Levodopa use, n (%)	59 (79.7%)	-	
Dopamine agonist, n (%)	28 (37.8%)	-	

COMT inhibitor, n (%)	4 (5.4%)	-	
MAO-B inhibitor, n (%)	21 (28.4%)	-	
Amantadine, n (%)	12 (16.2%)	-	
Levodopa equivalent daily dose (mg)	450.0 (200.0–712.5)	-	
Daily dietary intake	(n=68)	(n=64)	
Total energy (kCal)	2184.8 ± 501.5	2230.7 ± 571.6	0.624
Carbohydrate (g)	296.9 ± 72.5	297.2 ± 79.6	0.980
Protein (g)	89.7 ± 26.2	91.4 ± 25.6	0.707
- animal source	47.5 ± 15.9	48.6 ± 17.1	0.702
- plant source	42.2 ± 16.7	42.8 ± 16.5	0.836
Fat intake (g)	68.5 ± 26.2	69.6 ± 24.8	0.803
- animal source	39.8 ± 20.2	40.3 ± 19.4	0.889
- plant source	28.7 ± 12.4	29.3 ± 12.7	0.774
Fiber (g)	38.9 ± 17.1	39.6 ± 18.6	0.806
- Soluble fiber	5.2 ± 2.5	5.3 ± 2.5	0.733
- Insoluble fiber	19.0 ± 8.1	19.9 ± 9.0	0.575

**Supplementary Table 3.** Functional biomarkers of the oral microbiome using PICRUSt

Ortholog	Definition	Pathway	Module	p-value	FDR		
					q-value	PD	Control
	beta-glucoside operon transcriptional antiterminator			0.000208	0.234752	0.0316	0.0252
K02199	cytochrome c biogenesis protein CcmG, thiol:disulfide interchange protein DsbE			0.000304	0.234752	0.0447	0.0533
		ko00010, ko00260, ko00680, ko01100, ko01110, ko01120, ko01130, M00001, ko01200, M00002,					
K15634	probable phosphoglycerate mutase	ko01230	M00003	0.000569	0.234752	0.0326	0.0225
K06188	aquaporin Z			0.000613	0.234752	0.0239	0.0301
K06962	uncharacterized protein			0.000641	0.234752	0.0211	0.0159
K03546	DNA repair protein SbcC/Rad50			0.000811	0.234752	0.0406	0.035
		ko00500,					
K00689	dextranucrase	ko02020		0.000847	0.234752	0.0661	0.0371
K07493	putative transposase			0.000859	0.234752	0.0491	0.0325
K15539	cytoskeleton protein RodZ			0.001022	0.234752	0.0344	0.0407
	phospholipid/cholesterol/gamma-HCH transport system ATP-binding protein		M00210, M00669,				
K02065	protein	ko02010	M00670	0.001022	0.234752	0.0651	0.0733
	bacterial/archaeal transporter family						
K08978	protein			0.001582	0.234752	0.0401	0.0513
K19225	rhomoid protease GluP			0.001998	0.234752	0.0338	0.0277
K05988	dextranase	ko00500		0.002025	0.234752	0.0134	0.0078

K13732	fibronectin-binding protein A	ko05100		0.002546	0.234752	0.0149	0.0092	
K21125	mucin-5AC	ko04657		0.002869	0.234752	0.0235	0.0166	
K06148	ATP-binding cassette, subfamily C, bacterial			0.003105	0.234752	0.0719	0.063	
K19736	TetR/AcrR family transcriptional regulator, regulator of autoinduction and epiphytic fitness			0.003676	0.236216	0.0224	0.0171	
K03646	colicin import membrane protein			0.003871	0.236216	0.0687	0.074	
K06196	cytochrome c-type biogenesis protein			0.003871	0.236216	0.0902	0.102	
K09765	epoxyqueuosine reductase			0.004074	0.236216	0.0308	0.0369	
K17320	putative aldouronate transport system permease protein	ko02010	M00603	0.004127	0.236216	0.0203	0.026	
K02477	two-component system, LytTR family, response regulator			0.004745	0.241451	0.0284	0.0235	
K17318	putative aldouronate transport system substrate-binding protein	ko02010	M00603	0.004805	0.241451	0.0211	0.0273	
K12541	ATP-binding cassette, subfamily C, bacterial LapB	ko02010	M00330	0.005052	0.241852	0.0217	0.0281	
K07029	diacylglycerol kinase (ATP) thiamine-phosphate	ko01110		0.005052	0.241852	0.0413	0.0341	
K00788	pyrophosphorylase	ko00730,	ko01100,	0.005513	0.244934	0.0538	0.059	
K06950	uncharacterized protein	ko01100	M00127	0.005513	0.244934	0.0345	0.0278	
K12373	hexosaminidase	ko00511, ko00513, ko00520, ko00531, ko00603, ko00604,	ko01100,	M00079	0.006238	0.259034	0.0684	0.0826

					ko04142				
	polysaccharide biosynthesis transport								
K16554	protein		ko05111			0.006472	0.261413	0.0366	0.0417
K03547	DNA repair protein SbcD/Mre11					0.006795	0.262681	0.0357	0.0299
K15923	alpha-L-fucosidase 2		ko00511			0.007577	0.273064	0.0186	0.0242
	neurotransmitter:Na <sup>+</sup> symporter, NSS								
K03308	family					0.007577	0.273064	0.0551	0.0624
K19334	biofilm protein TabA					0.00824	0.277262	0.0276	0.0331
	two-component system, sensor								
K07718	histidine kinase YesM		ko02020	M00519		0.00824	0.277262	0.045	0.0556
	cyclomaltodextrinase / maltogenic								
K01208	alpha-amylase / neopullulanase		ko01100			0.008539	0.277262	0.0235	0.0291
K07494	putative transposase					0.008641	0.279278	0.029	0.0378
K01286	D-alanyl-D-alanine carboxypeptidase					0.008744	0.280666	0.0296	0.0221
	5-methylthioadenosine/S-								
K12960	adenosylhomocysteine deaminase		ko01100			0.008849	0.28079	0.0494	0.0619
K01436	amidohydrolase					0.008849	0.28079	0.0514	0.0428
K06199	fluoride exporter					0.009498	0.285211	0.0686	0.076
K16692	tyrosine-protein kinase Etk/Wzc					0.009723	0.286882	0.0226	0.017
	hemoglobin/transferrin/lactoferrin								
K16087	receptor protein					0.012255	0.286882	0.0362	0.0496
K01448	N-acetylmuramoyl-L-alanine amidase		ko01503	M00727		0.013727	0.288501	0.0802	0.066
K07238	zinc transporter, ZIP family					0.015354	0.296986	0.0265	0.0201
K12996	rhamnosyltransferase					0.015525	0.298433	0.0282	0.0226
			ko00052,						
			ko00511,						
			ko00600,						
K01190	beta-galactosidase		ko01100			0.01696	0.304242	0.0687	0.0786
	PTS system, cellobiose-specific IIC								
K02761	component		ko02060	M00275		0.019753	0.319929	0.0292	0.0231
	putative hydrolase of the HAD								
K07025	superfamily					0.020621	0.324901	0.0848	0.0761

	thiol:disulfide interchange protein						
K03673	DsbA	ko01503	M00728	0.021522	0.324901	0.0152	0.0197
	ATP-binding cassette, subfamily B,						
K06147	bacterial			0.021522	0.324901	0.3676	0.341
	N-acetylglucosamine-6-phosphate 2-						
K01788	epimerase	ko00520		0.021753	0.326271	0.0516	0.0602
		ko00511,					
		ko00600,					
K01186	sialidase-1	ko04142		0.022221	0.328618	0.0575	0.0712
	endo-alpha-N-						
K17624	acetylgalactosaminidase			0.022458	0.328618	0.027	0.0336
K19302	undecaprenyl-diphosphatase	ko00550		0.022458	0.328618	0.0665	0.0613
		ko00750,					
		ko01100,					
K00275	pyridoxamine 5'-phosphate oxidase	ko01120	M00124	0.022939	0.332302	0.0155	0.0202
		ko00230,					
		ko00240,					
		ko00760,					
		ko01100,					
K01081	5'-nucleotidase	ko01110		0.023428	0.334548	0.059	0.0476
	thiaminase (transcriptional activator	ko00730,					
K03707	TenA)	ko01100		0.025215	0.345598	0.0335	0.0396
	ATP-binding cassette, subfamily C,	ko02010,					
K20344	bacteriocin exporter	ko02024		0.025215	0.345598	0.0252	0.0168
	peptide methionine sulfoxide						
K12267	reductase msrA/msrB			0.026288	0.351448	0.0733	0.0798
		ko00230,					
		ko00250,					
		ko01100,					
		ko01110,	M00048,				
K01756	adenylosuccinate lyase	ko01130	M00049	0.026288	0.351448	0.0961	0.1061
K00812	aspartate aminotransferase	ko00220,		0.027971	0.362763	0.0604	0.0548





	family, response regulator AgrA	ko02024						
	two-component system, LytTR	ko02020,						
K07706	family, sensor histidine kinase AgrC	ko02024	M00495	0.03602	0.407602	0.0581	0.0384	
K07487	transposase			0.037107	0.412455	0.0641	0.0523	
K07124	uncharacterized protein			0.037476	0.413595	0.0584	0.054	
		ko00270,						
		ko00450,						
	5-	ko01100,						
	methyltetrahydropteroyltriglutamate-	ko01110,						
K00549	-homocysteine methyltransferase	ko01230	M00017	0.040538	0.430093	0.0936	0.086	
K03496	chromosome partitioning protein			0.044662	0.444841	0.0807	0.0741	
	sulfur-carrier protein							
K21147	adenylyltransferase/sulfurtransferase	ko04122		0.045528	0.446162	0.0422	0.0477	

**Supplementary Table 4.** Correlation between clinical symptoms and gut microbial abundance

<b>Feature</b>	<b>Bacteria</b>	<b>R square</b>	<b>P value</b>	<b>Q value</b>
UPDRS	Lactobacillus	0.21448	0.00002	0.0006
H&Y stage	Lactobacillus	0.2122	0.00002	0.0006
COMT inhibitor	Lactobacillus	0.1821	0.00002	0.0016
COMT inhibitor	Bifidobacterium	0.1721	0.00002	0.0016
Age	Prevotella	0.1521	0.00003	0.0016
UPDRS	Bifidobacterium	0.1352	0.00003	0.0016
Bristol scale	Prevotella	0.1318	0.00005	0.003
H&Y stage	Bifidobacterium	0.1292	0.00005	0.003
Constipation	Prevotella	0.12456	0.00007	0.003
Age	Prevotella	0.1193	0.00012	0.0057
Dysphagia	Bifidobacterium	0.1012	0.0003	0.012
Dysphagia	PAC001043	0.08509	0.00068	0.0155
Disease duration	Bifidobacterium	0.08401	0.00071	0.0163
Age	Parabacteroides	0.07936	0.0009	0.018
UPDR	PAC001043	0.07054	0.0014	0.0258
Age	Alistipes	0.06702	0.00167	0.0286
Amantadine	Lactobacillus	0.06343	0.00201	0.0301
Olfaction	Ruminococcus	0.0598	0.00241	0.0321
Disease duration	Lactobacillus	0.05773	0.00268	0.0338
H&Y stage	PAC001043	0.05613	0.0029	0.0348
Dysphagia	Roseburia	0.05288	0.00343	0.0376
Dysphagia	Lactobacillus	0.05264	0.00347	0.0378
COMT inhibitor	Oscillibacter	0.05187	0.00361	0.0392
H&Y stage	Sporobacter	0.04736	0.00454	0.0454